CME Presentations

CLL


Presentations


Speakers

  • Susan O'Brien, MD

    Susan O'Brien, MD

    Susan O'Brien, MD

    Associate Director for Clinical Science

    Susan O’Brien, MD, is the associate director for Clinical Science at the Chao Family Comprehensive Cancer Center, the medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, professor of medicine in the Department of Hematology and Oncology, and the endowed chair of Cancer Clinical Science at University of California, Irvine. She is an internationally recognized leader in the research of treatments for both acute and chronic lymphocytic leukemias. Dr O’Brien has been a principal investigator behind more than 100 funded clinical research protocols and has authored more than 900 articles in peer-reviewed journals. Her work is credited with improving cure rates for blood cancers, and she is routinely recognized on America’s Top Doctors.
  • Matthew Davids, MD, MMSc

    Matthew Davids, MD, MMSc

    Matthew Davids, MD, MMSc

    Director of Clinical Research and Associate Director of Chronic Lymphocytic Leukemia (CLL) Center, Division of Lymphoma

    Matthew Davids, MD, MMSc, is the director of Clinical Research and the associate director of the Chronic Lymphocytic Leukemia (CLL) Center in the Division of Lymphoma at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is also an associate professor of medicine at Harvard Medical School. Dr Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. He received his medical degree from Yale University School of Medicine in New Haven, Connecticut.

CME Information

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors


PIM Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
  • List the emerging combination regimens, including BTK inhibitors
  • Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL
  • Integrate patient perspectives and priorities into comprehensive care-team management of CLL
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the CLL Society (CLLS) and the Leukemia & Lymphoma Society (LLS).

This activity is supported by educational grants from AstraZeneca, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

PHYSICIAN CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSE EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

ENDURING CREDIT DESIGNATION STATEMENTS

PHYSICIAN CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSE EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.50 contact hours.

DATE OF RELEASE/EXPIRATION

Live Activity

Tuesday, August 24, 2021
1:00pm – 1:15pm ET: Emerging Combinations for Newly Diagnosed CLL
1:30pm – 2:00pm ET: High‐Risk Relapsed/Refractory (R/R) CLL

Enduring Material

The enduring material will be available from August 24, 2021 to October 22, 2022.

August 24, 2021 to October 22, 2022
Emerging Combinations for Newly Diagnosed CLL
High‐Risk Relapsed/Refractory (R/R) CLL

October 8, 2021 to October 22, 2022
Patient Selection

October 22, 2021 to October 22, 2022
Aligning Patient and Provider Goals

TARGET AUDIENCE

The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.

ESTIMATED TIME TO COMPLETE

Live activity – 45 minutes
Enduring activity – 1.5 hours

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Director of Clinical Research, Division of Lymphoma
Harvard Medical School
Dana-Farber Cancer Institute
Consulting Fees (e.g., advisory boards): AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Merck, Pharmacyclics LLC, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem
Susan M. O’Brien, MD
Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials and Research
Chao Family Endowed Chair for Cancer Clinical Science
Professor, Division of Hematology/Oncology, School of Medicine, University of California Irvine
Consulting Fees (e.g., advisory boards): AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Autolus, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, Merck, NOVA Research Company, Pharmacyclics LLC, Pfizer, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, Vida Ventures
Contracted Research: Acerta, Caribou, Kite, Gilead, Pharmacyclics LLC, Pfizer, Regeneron, Sunesis, TG Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.